An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria prior to Surgery:

- Suspected or histologically confirmed Stage IIA to IIIB NSCLC with disease that is
considered resectable

- Must be deemed eligible for complete resection and must agree to undergo standard of
care surgery for complete resection of NSCLC

- Treatment naive (no previous systemic treatment)

Inclusion Criteria prior to Treatment Randomization:

- Must have undergone complete surgical resection of their Stage IIA to IIIB NSCLC

- Must have adequately recovered from surgery at the time of randomization

- Minimal residual disease (MRD) positive results as detected by ctDNA

Exclusion Criteria prior to Surgery:

- Participants with known EGFR mutations which are sensitive to available targeted
inhibitor therapy (Prior to treatment randomization in select sites)

- Active, known or suspected autoimmune disease

- Participants with a condition requiring systemic treatment with either corticosteroids
(> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
days of randomization

Exclusion Criteria prior to Treatment Randomization:

- Must continue to meet Exclusion Criteria prior to Surgery

- Must have no evidence of metastatic disease after surgery

- Received a live/attenuated vaccine within 30 days of first treatment

Other protocol defined inclusion/exclusion criteria could apply